Sign In  |  Register  |  About Los Altos  |  Contact Us

Los Altos, CA
September 01, 2020 1:26pm
7-Day Forecast | Traffic

  • Search Hotels in Los Altos

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Summit Therapeu ADR (NQ: SMMT )

19.00 +0.58 (+3.15%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Summit Therapeu ADR

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Could Summit Therapeutics Become the Next Merck?
Recent developments are forcing comparisons between these two drugmakers. 
Via The Motley Fool
Why Phoenix Motor Shares Are Trading Higher By 150%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Summit Therapeutics Announces Completion of Enrollment in Its Phase III HARMONi Trial in 2L+ EGFRm NSCLC
From Summit Therapeutics Inc.
Via Business Wire
Where Will Summit Therapeutics Be in 3 Years?
There's a lot riding on how its collaborator's studies end up performing. 
Via The Motley Fool
Here's How Much $100 Invested In Summit Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In September 2024 – Where Do Tesla, Nvidia, Apple, DJT Stock Rank?
A look at the 20 most searched tickers on Benzinga Pro, which includes many familiar names and some penny stocks that may be less familiar. 
Via Benzinga
Has Summit Therapeutics Stock Already Peaked?
Summit Therapeutics stock is up a remarkable 700% this year. 
Via The Motley Fool
Is Summit Therapeutics Stock a Buy?
Its alliance with a successful foreign biotech could be decisive for the stock. 
Via The Motley Fool
Regeneron Pharma, Super Micro Computer And Global Payments Are Among Top 10 Large Cap Losers Last Week (Sept 23-Sept 27): Are The Others In Your Portfolio?
10 worst performing large-cap stocks last week: SMMT, MMYT, MEDP, REGN, GPN, AFRM, SMCI, FTI, FCNCA, NOW. Are they in your portfolio? 
Via Benzinga
2 High-Potential Growth Stocks You Shouldn't Overlook
These two growth stocks have plenty of room to run. 
Via The Motley Fool
Better Rising Biotech: Viking Therapeutics vs. Summit Therapeutics
One of them is performing much better than the other this year. 
Via The Motley Fool
2 Stocks Up Over 700% in 2024 That Could Soar Even Further
These relatively small companies are developing new cancer therapies that could generate billions in annual sales. 
Via The Motley Fool
Novo Nordisk, Chewy And FedEx Are Among Top 10 Large Cap Losers Last Week (Sept 15-Sept 21): Are The Others In Your Portfolio?
10 large-cap stocks worst performers in last week: SMMT -23.61%, KSPI -21.66%, BMRN -16.74%, RIVN -13.26%, FDX -11.08%, BNTX -9.01%, AJG -7.17%, CHWY -6.97%, NVO -6.93%, MUSA -6.90% 
Via Benzinga
This Stock Is Crushing Nvidia's Performance This Year: Is It Too Late to Buy?
How long will the momentum last? 
Via The Motley Fool
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Via AB Newswire
Industry Update: 3 Exciting Precision Oncology Players to Watch Following Summit’s Meteoric Rise: Silexion, Nuvectis, Scorpian
Summit Therapeutics' rise could signal emerging opportunities in precision oncology such Nuvectis Pharma (NASDAQ: NVCT), Silexion (NASDAQ:SLXN), and Scorpion leading the charge. 
Via News Direct
Is It Too Late to Buy Summit Therapeutics Stock After Its Almost 10X Gain This Year?
The sky might be the limit for a biotech company with a pipeline candidate that beat the world's top-selling drug in a late-stage clinical study. 
Via The Motley Fool
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
There's a lot of hope for ivonescimab, but are investors being a bit too bullish? 
Via The Motley Fool
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
BioNTech is developing a drug similar to Summit's and shares have skyrocketed over the past four trading days. 
Via Investor's Business Daily
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Merck reported topline data from its HERTHENA-Lung02 phase 3 trial of patritumab deruxtecan in EGFR-mutated non-small cell lung cancer, showing significant improvement in progression-free survival... 
Via Benzinga
Here's Why Everyone's Talking About Summit Therapeutics
Find out why positive results from a Summit Therapeutics study keep pushing up BioNTech and Instil Bio stock. 
Via The Motley Fool
Alphabet To $200? Here Are 10 Top Analyst Forecasts For Monday
Via Benzinga
Promising Anti-Tumor Activity and Safety of Ivonescimab in Combination Therapies in CRC, TNBC, and HNSCC Featured at ESMO 2024
From Summit Therapeutics Inc.
Via Business Wire
Chewy, Broadcom And MicroStrategy Are Among Top 10 Large Cap Stock Gainers Last Week (Sep 8-Sep 14): Are The Others In Your Portfolio?
These ten stocks saw significant gains last week, with Summit Therapeutics up 98.32% and BioNTech up 31.77%. Analysts also raised price targets for Applovin and Arm Holdings. 
Via Benzinga
Up More Than 500% in 2024. Can Instil Bio Keep Rocketing Higher?
A candidate that Instil Bio in-licensed this August is similar to a candidate that recently outperformed the world's top-selling cancer therapy. 
Via The Motley Fool
Why Summit Therapeutics Skyrocketed 123% This Week
Better-than-expected trial data means Summit's bispecific antibody could replace the blockbuster Keytruda as a standard of care for certain lung cancers. 
Via The Motley Fool
Why Summit Therapeutics Stock Is Soaring Again Today
This high-flying biotech stock is moving even higher -- and for good reason. 
Via The Motley Fool
Signet Jewelers Posts Better-Than-Expected Earnings, Joins NETGEAR, Lovesac And Other Big Stocks Moving Higher On Thursday
Via Benzinga
Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale
The company is adding onto its success outperforming Merck's top drug in lung cancer patients. 
Via Investor's Business Daily
Summit Therapeutics Surges on Trial Results: Time to Buy?
Summit Therapeutics has surged almost 100% this week, driven by positive Phase III trial results for its cancer therapy Ivonescimab. 
Via MarketBeat
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 LosAltos.com & California Media Partners, LLC. All rights reserved.